{"created":"2023-07-27T06:39:49.328135+00:00","id":28421,"links":{},"metadata":{"_buckets":{"deposit":"285040c9-3a71-49b9-b691-47304529d811"},"_deposit":{"created_by":3,"id":"28421","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"28421"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00028421","sets":["4200:1874:1875"]},"author_link":["49562","91488","20737","49560","87","40","85011","109814","49561","49564","43"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-01-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"121","bibliographicPageStart":"115","bibliographicVolumeNumber":"36","bibliographic_titles":[{"bibliographic_title":"European Journal of Nuclear Medicine and Molecular Imaging"}]}]},"item_4_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小川, 数馬"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"川井, 恵一"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"柴, 和弘"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"森, 厚文"}],"nameIdentifiers":[{},{}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose: We have developed a 186Re-mercaptoacetylglycylglycylglycine complex-conjugated bisphosphonate (186Re-MAG3-HBP) for the treatment of painful bone metastases. We assumed competitive inhibitors of protein binding to be useful for procuring a favorable biodistribution of 186Re-MAG3-HBP for the palliation of bone pain because it has been reported that the concurrent administration of 99mTc-MAG3 and drugs with high affinity for serum protein produced competitive displacement at specific binding sites and enhanced total clearance and tissue distribution. Methods: The displacement effects of several protein-binding inhibitors on the protein binding of 186Re-MAG3-HBP were investigated. Biodistribution experiments were performed by intravenously administering 186Re-MAG3-HBP into rats with ceftriaxone as a competitive protein-binding inhibitor or saline. Results: The protein binding of 186Re-MAG3-HBP in rat serum, human serum, and a human serum albumin solution was significantly decreased by the addition of ceftriaxone, which has high affinity for binding site I on serum albumin. In the biodistribution experiments, pretreatment with ceftriaxone enhanced the clearance of the radioactivity of 186Re-MAG3-HBP in blood and nontarget tissues but had no effect on accumulation in bone. Conclusions: The findings suggested that the use of protein-binding competitive inhibitors would be effective in improving the pharmacokinetics of radiopharmaceuticals with high affinity for serum protein. © 2008 Springer-Verlag.","subitem_description_type":"Abstract"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学疾患モデル総合研究センター / 金沢大学学際科学実験センターアイソトープ総合研究施設","subitem_description_type":"Other"}]},"item_4_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00028408","subitem_identifier_reg_type":"JaLC"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Verlag (Germany)"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1007/s00259-008-0925-8","subitem_relation_type_select":"DOI"}}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA1161516X","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1619-7070","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ogawa, Kazuma"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"Mukai, Takahiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawai, Keiichi"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"Takamura, Norito"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hanaoka, Hirofumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hashimoto, Kazuyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shiba, Kazuhiro"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Mori, Hirofumi"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Saji, Hideo"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-05"}],"displaytype":"detail","filename":"ME-PR-OGAWA-K-115.pdf","filesize":[{"value":"303.9 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-OGAWA-K-115.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/28421/files/ME-PR-OGAWA-K-115.pdf"},"version_id":"f96d0a5e-ce86-4e36-92c9-f6ac35b51b73"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases"}]},"item_type_id":"4","owner":"3","path":["1875"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-05"},"publish_date":"2017-10-05","publish_status":"0","recid":"28421","relation_version_is_last":true,"title":["Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-07-27T10:18:15.388151+00:00"}